Fibroblast growth factor signaling in metabolic regulation

116Citations
Citations of this article
225Readers
Mendeley users who have this article in their library.

Abstract

The prevalence of obesity is a growing health problem. Obesity is strongly associated with several comorbidities, such as non-alcoholic fatty liver disease, certain cancers, insulin resistance, and type 2 diabetes, which all reduce life expectancy and life quality. Several drugs have been put forward in order to treat these diseases, but many of them have detrimental side effects. The unexpected role of the family of fibroblast growth factors in the regulation of energy metabolism provides new approaches to the treatment of metabolic diseases and offers a valuable tool to gain more insight into metabolic regulation. The known beneficial effects of FGF19 and FGF21 on metabolism, together with recently discovered similar effects of FGF1 suggest that FGFs and their derivatives carry great potential as novel therapeutics to treat metabolic conditions. To facilitate the development of new therapies with improved targeting and minimal side effects, a better understanding of the molecular mechanism of action of FGFs is needed. In this review, we will discuss what is currently known about the physiological roles of FGF signaling in tissues important for metabolic homeostasis. In addition, we will discuss current concepts regarding their pharmacological properties and effector tissues in the context of metabolic disease. Also, the recent progress in the development of FGF variants will be reviewed. Our goal is to provide a comprehensive overview of the current concepts and consensuses regarding FGF signaling in metabolic health and disease and to provide starting points for the development of FGF-based therapies against metabolic conditions.

References Powered by Scopus

FGF-21 as a novel metabolic regulator

1840Citations
N/AReaders
Get full text

Cellular signaling by fibroblast growth factor receptors

1614Citations
N/AReaders
Get full text

The FGF family: Biology, pathophysiology and therapy

1583Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Mechanisms of NAFLD development and therapeutic strategies

2890Citations
N/AReaders
Get full text

Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease

359Citations
N/AReaders
Get full text

Therapies in non-alcoholic steatohepatitis (NASH)

202Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Nies, V. J. M., Sancar, G., Liu, W., Van Zutphen, T., Struik, D., Yu, R. T., … Downes, M. R. (2016). Fibroblast growth factor signaling in metabolic regulation. Frontiers in Endocrinology. Frontiers Media S.A. https://doi.org/10.3389/fendo.2015.00193

Readers over time

‘16‘17‘18‘19‘20‘21‘22‘23‘24‘25015304560

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 99

67%

Researcher 31

21%

Professor / Associate Prof. 13

9%

Lecturer / Post doc 5

3%

Readers' Discipline

Tooltip

Biochemistry, Genetics and Molecular Bi... 61

43%

Agricultural and Biological Sciences 36

25%

Medicine and Dentistry 35

25%

Pharmacology, Toxicology and Pharmaceut... 10

7%

Article Metrics

Tooltip
Social Media
Shares, Likes & Comments: 95

Save time finding and organizing research with Mendeley

Sign up for free
0